These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 3662286)

  • 1. 3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: a new class of cholesterol-lowering agents.
    Gordon DJ; Rifkind BM
    Ann Intern Med; 1987 Nov; 107(5):759-61. PubMed ID: 3662286
    [No Abstract]   [Full Text] [Related]  

  • 2. Worldwide experience with simvastatin/lovastatin.
    Walker JF
    Eur Heart J; 1992 Jul; 13 Suppl B():21-2. PubMed ID: 1644097
    [No Abstract]   [Full Text] [Related]  

  • 3. Long-term clinical tolerance of lovastatin and simvastatin.
    Bilheimer DW
    Cardiology; 1990; 77 Suppl 4():58-65. PubMed ID: 2073673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia.
    Hsu I; Spinler SA; Johnson NE
    Ann Pharmacother; 1995; 29(7-8):743-59. PubMed ID: 8520093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 3-Hydroxy-3-methylglutaryl--coenzyme A reductase inhibitors in the treatment of hypercholesterolemia.
    Hoeg JM; Brewer HB
    JAMA; 1987 Dec; 258(24):3532-6. PubMed ID: 3316727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lovastatin: an HMG-CoA reductase inhibitor for lowering cholesterol.
    Frishman WH; Rapier RC
    Med Clin North Am; 1989 Mar; 73(2):437-48. PubMed ID: 2645482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipid lowering drugs in atherosclerosis--the HMG-CoA reductase inhibitors.
    Mantell G
    Clin Exp Hypertens A; 1989; 11(5-6):927-41. PubMed ID: 2676263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanism of action and biological profile of HMG CoA reductase inhibitors. A new therapeutic alternative.
    Slater EE; MacDonald JS
    Drugs; 1988; 36 Suppl 3():72-82. PubMed ID: 3076125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
    Lennernäs H; Fager G
    Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Statins and the acute-phase response.
    Munford RS
    N Engl J Med; 2001 Jun; 344(26):2016-8. PubMed ID: 11430332
    [No Abstract]   [Full Text] [Related]  

  • 11. [Effect of cholesterol reducing therapy with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor on secondary prevention after myocardial infarction in Japanese patients].
    Tachibana E; Watanabe I; Nagao K; Kanmatsuse K
    J Cardiol; 2000 Apr; 35(4):277-85. PubMed ID: 10791271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results of the primary outcome measure and clinical events from the Asymptomatic Carotid Artery Progression Study.
    Probstfield JL; Margitic SE; Byington RP; Espeland MA; Furberg CD
    Am J Cardiol; 1995 Sep; 76(9):47C-53C. PubMed ID: 7572686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Residual effects of lovastatin and simvastatin on urinary mevalonate excretions in patients with familial hypercholesterolemia.
    Pappu AS; Bacon SP; Illingworth DR
    J Lab Clin Med; 2003 Apr; 141(4):250-6. PubMed ID: 12677170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generalized eczematous skin rash possibly due to HMG-CoA reductase inhibitors.
    Krasovec M; Elsner P; Burg G
    Dermatology; 1993; 186(4):248-52. PubMed ID: 8513188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of cholesterol-lowering treatment in Japanese elderly patients with coronary artery disease and normal cholesterol level using 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.
    Chikamori T; Sugimoto K; Hamada T; Kitaoka H; Furuno T; Seo H; Doi Y
    J Cardiol; 2000 Feb; 35(2):95-101. PubMed ID: 10713930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A 6-month trial of simvastatin (HMG-CoA reductase inhibitor) in the treatment of hypercholesterolaemia.
    Steyn K; Weich HF; Vermaak WJ; Marais AD; Omar MA; Van Gelder AL; Fourie J; Kotze TJ; Stander I; Firth JC
    S Afr Med J; 1991 Jun; 79(11):639-45. PubMed ID: 2047945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Cholesterol-reducing medications-a new therapeutic option for multiple sclerosis? Statins as immunomodulators].
    Neuhaus O; Wiendl H; Kieseier BC; Archelos JJ; Hartung HP
    Nervenarzt; 2003 Aug; 74(8):704-7. PubMed ID: 12904873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of lipids on the pathogenesis of progressive renal failure: role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in the prevention of glomerulosclerosis.
    Guijarro C; Keane WF
    Miner Electrolyte Metab; 1996; 22(1-3):147-52. PubMed ID: 8676808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase.
    Blum CB
    Am J Cardiol; 1994 May; 73(14):3D-11D. PubMed ID: 8198021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of familial hypercholesterolemia in children and adolescents: effect of lovastatin. Canadian Lovastatin in Children Study Group.
    Lambert M; Lupien PJ; Gagné C; Lévy E; Blaichman S; Langlois S; Hayden M; Rose V; Clarke JT; Wolfe BM; Clarson C; Parsons H; Stephure DK; Potvin D; Lambert J
    Pediatrics; 1996 May; 97(5):619-28. PubMed ID: 8628597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.